J
Jean-Jacques Body
Researcher at Université libre de Bruxelles
Publications - 397
Citations - 21506
Jean-Jacques Body is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Zoledronic acid. The author has an hindex of 70, co-authored 384 publications receiving 19608 citations. Previous affiliations of Jean-Jacques Body include The Breast Cancer Research Foundation & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines
Fabrice Journe,Nicolas Magne,Carole Chaboteaux,Eric Kinnaert,Frieder Bauss,Jean-Jacques Body +5 more
TL;DR: The in vitro study examined the cytotoxic effects resulting from combinations of ibandronate and ionising radiations in various sequences on breast cancer cells to provide a rationale for associating bisphosphonates and radiotherapy for the treatment of bone metastases from breast cancer.
Journal ArticleDOI
Regulation of lymphocyte calcitonin receptors by interleukin-1 and interleukin-6.
TL;DR: IL-1 and IL-6 can induce a marked apparent loss of CT binding sites on normal T-lymphocytes at concentrations known to be active on bone metabolism at concentrationsKnowing that these cytokines are involved in bone metabolism, their influence on the binding parameters of labeled salmon calcitonin on lymphocytes is examined.
Journal ArticleDOI
Calcitonin reserve in different stages of atrophic autoimmune thyroiditis.
TL;DR: CT deficiency occurs in AAT and is more severe in hypothyroid patients than in earlier stages of AAT, with markedly reduced CT-secretory reserve in group 4.
Journal ArticleDOI
Circulating concentrations of interleukin-6 in cancer patients and their pathogenic role in tumor-induced hypercalcemia.
Bernadette Vanderschueren,Jean Claude Dumon,Véronique Oleffe,C. Heymans,Jean Gerain,Jean-Jacques Body +5 more
TL;DR: The data indicate that increased circulating levels of IL-6 only contribute in a minor way to the osteolytic process in patients with tumor-induced hypercalcemia, and no significant correlations betweenIL-6 concentrations and any of the biochemical parameters studied are found.